Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.Learn More
Our pipeline includes several novel clinical-stage drug candidates for cancer treatment and protection from lethal radiation.
Our lead product candidates are entolimod (CBLB502), which we are developing for a biodefense indication and as an oncology drug, and Curaxin CBL0137, our lead oncology product candidate.
We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.
Enrollment is open for our therapeutic clinical trials for various indications with oncology drug candidates in the pipeline.